Evolus Inc EOLS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Evolus Launches Wings by Evolus, a New Charitable Platform to Mobilize Its Community in Support of Important Causes
-
A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture
-
Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook
-
Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New Zealand
-
Evolus to Report Second Quarter Financial Results on August 5, 2026
-
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
-
Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality
Trading Information
- Previous Close Price
- $7.69
- Day Range
- $6.91–7.72
- 52-Week Range
- $3.86–9.31
- Bid/Ask
- $7.01 / $7.11
- Shares Outstanding
- 66.05M
- Market Cap
- $471.60M
- Volume/Avg
- 2M / 900,188
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.47
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 353
- Website
- https://www.evolus.com
Valuation
|
Metric
|
EOLS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 1.47 |
Price/Cash Flow | 515.45 |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
EOLS
|
|---|---|
Quick Ratio | 1.09 |
Current Ratio | 1.70 |
Interest Coverage | −1.16 |
Quick Ratio
EOLS
Profitability
|
Metric
|
EOLS
|
|---|---|
Return on Assets (Normalized) | −7.26% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −3.63% |
Return on Assets
EOLS
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|n%%DGp$ | LOCK|Xg@% | $67B | |||
| Teva Pharmaceutical Industries Ltd
TEVA
| LOCK|>bvX>Y#W | LOCK|Wd?p | $46B | |||
| Haleon PLC ADR
HLN
| LOCK|wYL%N>S | LOCK|HCS | $38B | |||
| Zoetis Inc Class A
ZTS
| LOCK|^!w$g$DX | LOCK|!& | $29B | |||
| Viatris Inc
VTRS
| LOCK|@$T#R% | LOCK|j>K | $20B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|Kb | LOCK|@QV | $11B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|?hpYRq% | LOCK|k@n | $10B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|L>!>%< | LOCK|@NR | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|$?spn! | LOCK|G!jx | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|r>k$@z | LOCK|M# | $2B |
United States